CSDC2 (cold shock domain containing C2) is an RNA-binding protein that functions as a regulator of mRNA stability and translation. It specifically binds to the 3'-UTR regions of histone H1 and H3.3 mRNAs at their polyadenylation signals, suggesting a role in negative regulation of histone variant synthesis in developing brain tissue [UniProt Function]. The protein exhibits context-dependent subcellular localization: cytoplasmic localization in differentiated zones coincides with developmental differentiation, while nuclear localization appears in proliferative regions 1. CSDC2 demonstrates broad disease relevance across multiple pathologies. In hepatocellular carcinoma, CSDC2 emerged as one of seven key genes in a cancer stem cell index-based prognostic model for survival prediction and risk stratification 2. In glioblastoma, CSDC2 was identified as significantly underexpressed and potentially acts as a tumor suppressor 3, with negative correlation to the oncogenic lncRNA H19 4. In heart failure, CSDC2 was identified as a key differentially expressed gene in cardiomyocytes, with expression alterations associated with disrupted fatty acid metabolism and oxidative phosphorylation 56. Additionally, CSDC2 shows causal association with sleep apnea based on brain proteomic and transcriptomic evidence 7. These findings suggest CSDC2 may serve as a multi-disease biomarker with potential clinical utility in cancer diagnosis, heart disease stratification, and sleep disorder assessment.